SEC Form 4 · accession 0001209191-17-050188
Tvardi Therapeutics, Inc. · TVRD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mani Mohindru
Officer — CFO & Chief Strategy Officer
Period of report
Aug 15, 2017
Accepted (ET)
Aug 24, 2017 · 5:52 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001346830
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F1 | $14.06 | Aug 15, 2017 | A | 385,000 | A | — | Aug 15, 2027 | Common Stock | 385,000 | 385,000 | D |
Explanation of responses
- F1One-fourth (1/4th) of the shares shall vest and become exercisable on August 15, 2018; the balance of the shares shall vest and become exercisable in a series of 36 successive equal monthly installments measured from August 15, 2018, subject to the reporting person's continuous service with the issuer as of each such date.